Artificial intelligence to assess changes in ECGs may represent a novel method to evaluate disease status and treatment response to mavacamten in patients with obstructive hypertrophic cardiomyopathy, researchers reported.
“Although hypertrophic cardiomyopathy (HCM) causes significant morbidity and is a leading cause of sudden death in adolescents, initial detection remains difficult,” Geoff Tison, MD, MPH, cardiologist and assistant professor in the division of cardiology at the University of California, San Francisco (UCSF), and colleagues wrote. “Although echocardiography